Consider drug efficacy before first-in-human trials.
Jonathan
J
Kimmelman
Carole
C
Federico
D000818:Animals; D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics / Q000379:methods* / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000191:economics / Q000379:methods* / Q000592:standards*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000191:economics / Q000517:prevention & control*; D032984:Ethics, Research; D005602:France; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D051379:Mice; D023421:Models, Animal; D061214:Patient Safety / Q000592:standards*; D012107:Research Design / Q000592:standards*; D018570:Risk Assessment / Q000592:standards; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration